Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97 patients with pancreatic ductal adenocarcinoma with circulating tumor DNA. Mutations were most frequently detected in patients with locally advanced and metastatic disease (Abstract 753).
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet r...
Eyal Meiri, MD, of the Cancer Treatment Centers of America at Southeastern Regional Medical Center, discusses his findings on heavily pretreated patients with colorectal canc...
Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cance...
Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whethe...
Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advance...